Aptinyx Inc.

OTCPK:APTX Stock Report

Market Cap: US$6.5m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Aptinyx Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Aptinyx.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth25.4%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Seeking Alpha • Aug 12

Aptinyx musculoskeletal pain drug NYX-2925 fails mid-stage study

Aptinyx (NASDAQ:APTX) said its oral medicine NYX-2925 did not show statistically significant separation from placebo in reducing pain, failing to meet the main goal of a phase 2b trial. The study evaluated 2 doses (50mg-100mg) of the drug versus placebo in ~300 patients with fibromyalgia — a disorder that causes widespread musculoskeletal pain. The main goal was the change from baseline in average daily pain as reported on the 0-to-10 numeric rating scale (NRS) during week 12 of the study. The company said that both doses did not show statistically significant separation from placebo. Patients on NYX-2925 at both doses showed a trend toward clinically meaningful improvement in pain, and some secondary goals, versus placebo by week 4. However, by week 12, the placebo group improved such that, although NYX-2925 remained numerically better, the separation was not clinically meaningful, Aptinyx said in an Aug. 12 press release. NYX-2925 was well tolerated in the study, and no concerning safety issues were seen, according to the company. Aptinyx added that detailed data from the study continue to be evaluated.
Analysis Article • Aug 18

We're Keeping An Eye On Aptinyx's (NASDAQ:APTX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 21

Aptinyx: CNS Drug Discoverer With Depressed Price

APTX stock went into long-term depression following a failed trial in 2019. However, the company has continued progressing its oral NMDA receptor modulator in the same indication, in a subgroup. The company has a decent amount of cash.
Analysis Article • Apr 13

Aptinyx (NASDAQ:APTX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Mar 09

Did You Miss Aptinyx's (NASDAQ:APTX) 15% Share Price Gain?

Aptinyx Inc. ( NASDAQ:APTX ) shareholders might be concerned after seeing the share price drop 21% in the last month...
Analysis Article • Jan 30

What Kind Of Shareholders Hold The Majority In Aptinyx Inc.'s (NASDAQ:APTX) Shares?

The big shareholder groups in Aptinyx Inc. ( NASDAQ:APTX ) have power over the company. Generally speaking, as a...
Analysis Article • Dec 26

Have Insiders Been Buying Aptinyx Inc. (NASDAQ:APTX) Shares This Year?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Analysis Article • Nov 27

What Type Of Returns Would Aptinyx's(NASDAQ:APTX) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Aptinyx Inc. (NASDAQ:APTX) shareholders should be happy to see the share price up 15% in the last month. But that is...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aptinyx has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:APTX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2023N/A-66-55-55N/A
12/31/2022N/A-65-60-60N/A
9/30/2022N/A-72-68-68N/A
6/30/2022N/A-78-68-68N/A
3/31/2022N/A-80-70-70N/A
12/31/20211-75-63-63N/A
9/30/20211-67-52-52N/A
6/30/20211-57-47-47N/A
3/31/20212-50-40-40N/A
12/31/20202-50-43-42N/A
9/30/20202-52-50-50N/A
6/30/20203-56-48-48N/A
3/31/20204-55-50-49N/A
12/31/20194-57-52-52N/A
9/30/20194-58-52-52N/A
6/30/20194-57-53-53N/A
3/31/20195-58-53-52N/A
12/31/20187-53-48-47N/A
9/30/20187-46-41-41N/A
6/30/20187-40-38-37N/A
3/31/20186-35-36-35N/A
12/31/20175-32-34-33N/A
12/31/201610-15N/A-20N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if APTX's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if APTX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if APTX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if APTX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if APTX's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if APTX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/01/03 08:40
End of Day Share Price 2023/12/29 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aptinyx Inc. is covered by 11 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gary NachmanBMO Capital Markets Equity Research
Charles DuncanCantor Fitzgerald & Co.
Raghuram SelvarajuH.C. Wainwright & Co.